![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will support Magnet's approach to the discovery and development of TrueGlues™, compounds inducing cooperative protein-protein interactions and will advance its portfolio spanning several indications, including oncology, cardiovascular, and immune disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newpath Partners
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 19, 2023